Thyroid carcinoma cells are resistant to FAS-mediated apoptosis but sensitive to tumor necrosis factor-related apoptosis-inducing ligand

Cancer Research

Volumn 60, Issue 15, 2000, Pages 4122-4129

  Mitsiades, N ^a   Poulaki, V ^a   Tseleni Balafouta, S ^a   Koutras, D A ^a   Stamenkovic, I ^a  

^a DANA FARBER CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CASPASE; CELL SURFACE RECEPTOR; LIGAND; PROTEIN INHIBITOR; RECOMBINANT PROTEIN; TUMOR NECROSIS FACTOR;

ANTIGEN EXPRESSION; APOPTOSIS; ARTICLE; CANCER CELL CULTURE; CONTROLLED STUDY; ENZYME ACTIVATION; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOBLOTTING; IMMUNOHISTOCHEMISTRY; PRIORITY JOURNAL; PROTEIN SYNTHESIS INHIBITION; REGULATORY MECHANISM; THYROID CARCINOMA;

ADULT; AGED; ANTIGENS, CD8; ANTIGENS, CD95; APOPTOSIS; APOPTOSIS REGULATORY PROTEINS; BLOTTING, WESTERN; CARCINOMA, PAPILLARY; CASPASES; ENZYME ACTIVATION; FEMALE; HUMANS; INTERFERON TYPE II; MALE; MEMBRANE GLYCOPROTEINS; MIDDLE AGED; RECEPTORS, TNF-RELATED APOPTOSIS-INDUCING LIGAND; RECEPTORS, TUMOR NECROSIS FACTOR; RECOMBINANT FUSION PROTEINS; SIGNAL TRANSDUCTION; THYROID NEOPLASMS; TNF-RELATED APOPTOSIS-INDUCING LIGAND; TUMOR CELLS, CULTURED; TUMOR NECROSIS FACTOR-ALPHA;

EID: 0033883775     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (57)

1. Fas and rumor necrosis factor receptor-mediated cell death: Similarities and distinctions
2. Apoptosis signaling by death receptors
3. Cell-autonomous Fas (CD95)/Fas-ligand interaction mediates activation-induced apoptosis in T-cell hybridomas
4. Fas(CD95)/FasL interactions required for programmed cell death after T-cell activation
5. Fas and perforin pathways as major mechanisms of T cell-mediated cytotoxicity
6. Fas ligand is present in tumors of the Ewing's sarcoma family and is cleaved into a soluble form by a metalloproteinase
7. Fas-mediated apoptosis in seven human prostate cancer cell lines: Correlation with tumor stage
8. Identification and characterization of a new member of the TNF family that induces apoptosis
9. Induction of apoptosis by Apo-2 ligand, a new member of the tumor necrosis factor cytokine family
10. The receptor for the cytotoxic ligand TRAIL
11. An antagonist decoy receptor and a death domain-containing receptor for TRAIL
12. Control of TRAIL-induced apoptosis by a family of signaling and decoy receptors
13. TRAIL-R2: A novel apoptosis-mediating receptor for TRAIL
14. Characterization of two receptors for TRAIL
15. Molecular cloning and expression of the Fas ligand, a novel member of the tumor necrosis factor family
16. Apoptosis, and Fas expression in human fetal membranes
17. Fas ligand-induced apoptosis as a mechanism of immune privilege
18. A role for CD95 ligand in preventing graft rejection
19. Fas/Fas ligand up-regulation and Bcl-2 down-regulation may be significant in the pathogenesis of Hashimoto's thyroiditis
20. Apoptosis in thyroid diseases: A histochemical study
21. Thyroid-stimulating hormone inhibits Fas antigen-mediated apoptosis of human thyrocytes in vitro
22. Fas (APO-1, CD95)-mediated apoptosis in thyroid cells is regulated by a labile protein inhibitor
23. Inflammatory cytokine regulation of Fas-mediated apoptosis in thyroid follicular cells
24. Potential involvement of Fas and its ligand in the pathogenesis of Hashimoto' s thyroiditis
25. TRAIL death pathway expression and induction in thyroid follicular cells
26. Identification of rapid turnover transcripts overexpressed in thyroid tumors and thyroid cancer cell lines: Use of a targeted differential RNA display method to select for mRNA subsets
27. Membrane oligomerization and cleavage activates the caspase-8 (FLICE/MACHα1) death signal
28. Fas ligand expression in thyroid carcinomas: A potential mechanism of immune evasion
29. Two CD95 (APO-1/Fas) signaling pathways
30. Fas, and Fas ligand interactions suppress melanoma lung metastasis
31. Lymphocyte apoptosis induced by CD95 (APO-1/Fas) ligand-expressing tumor cells: A mechanism of immune evasion?
32. Inhibition of death receptor signals by cellular FLIP
33. Inhibition of death receptor signaling by FLICE-inhibitory protein as a mechanism for immune escape of tumors
34. Immune escape of tumors in vivo by expression of cellular FLICE-inhibitory protein
35. The inhibitor of death receptor signaling. FLICE-inhibitory protein defines a new class of tumor progression factors
36. Characterization of FAP-1 expression and function in thyroid follicular cells
37. The correlation between papillary thyroid carcinoma and lymphocytic infiltration in the thyroid gland
38. Papillary thyroid cancer treated at the Mayo Clinic, 1946 through 1970: Initial manifestations, pathologic findings, therapy, and outcome
39. Chronic thyroiditis as a favorable prognostic factor in papillary thyroid carcinoma
40. Hashimoto's thyroiditis and carcinoma of the thyroid gland
41. Coexistent carcinoma of the thyroid gland and Hashimoto's thyroiditis
42. Lymphocytic infiltration in thyroid neoplasms. Preliminary prognostic assessments
43. Therapeutic usefulness of wild-type p53 gene introduction in a p53-null anaplastic thyroid carcinoma cell line
44. p53 re-expression inhibits proliferation and restores differentiation of human thyroid anaplastic carcinoma cells
45. Effects of p53-expressing adenovirus on the chemosensitivity and differentiation of anaplastic thyroid cancer cells
46. Fas-associated death domain protein interleukin-1β-converting enzyme 2 (FLICE2), an ICE/Ced-3 homologue, is proximally involved in CD95- and p55-mediated death signaling
47. Lethal effect of the anti-Fas antibody in mice
48. Passive immunization against cachectin/tumor necrosis factor protects mice from lethal effect of endotoxin
49. Tumoricidal activity of tumor necrosis factor-related apoptosis-inducing ligand in vivo
50. Safety and antitumor activity of recombinant soluble Apo2 ligand
51. Cloning and characterization of TRAIL-R3, a novel member of the emerging TRAIL receptor family
52. The novel receptor TRAIL-R4 induces NF-κB and protects against TRAIL-mediated apoptosis, yet retains an incomplete death domain
53. TRUNDD, a new member of the TRAIL receptor family that antagonizes TRAIL signalling
54. A novel receptor for Apo2L/TRAIL contains a truncated death domain
55. Intracellular regulation of TRAIL-induced apoptosis in human melanoma cells
56. Chemotherapy augments TRAIL-induced apoptosis in breast cell lines
57. Relation of TNF-related apoptosis-inducing ligand (TRAIL) receptor and FLICE-inhibitory protein expression to TRAIL-induced apoptosis of melanoma